---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-136408"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2024-12-16T23:59:59+00:00"
generated_at: "2026-05-29T03:14:04.004461+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# FibroGen appoints David DeLucia as CFO effective Dec 16, 2024

## Summary
- David DeLucia, previously VP of FP&A and IR, promoted to CFO, succeeding Juan Graham who stepped down Dec 15.
- DeLucia has nearly 15 years life sciences finance experience; previously at TherapeuticsMD and JP Morgan Asset Mgmt.
- As CFO, DeLucia will oversee finance, treasury, IR; reports to CEO Thane Wettig.
- Severance terms include 9 months salary for ordinary termination; 12 months salary plus bonus & equity vesting for CIC termination.
- Company highlights advancing FG-3246 ADC and companion diagnostic FG-3180 alongside roxadustat performance.

## SEC filing metadata
- accession: 0000950170-24-136408
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2024-12-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017024136408/0000950170-24-136408-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017024136408/fgen-20241216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-136408
- JSON: https://secwatch.observer/filing/0000950170-24-136408.json
- Plain text: https://secwatch.observer/filing/0000950170-24-136408.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.